Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company earned ($0.42) EPS. The firm’s revenue was down 57.8% compared to the same quarter last year.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $7.51 on Friday. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.91 and a beta of 0.86. The firm’s 50 day simple moving average is $7.72 and its 200 day simple moving average is $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a fifty-two week low of $5.60 and a fifty-two week high of $14.12.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.